InflaRx N.V. Highlights Promise of INF904 at R&D Event
Ticker: IFRX · Form: 6-K · Filed: Jun 5, 2024 · CIK: 1708688
Sentiment: neutral
Topics: R&D, drug-development, immuno-dermatology
TL;DR
InflaRx hosted an R&D event on June 5th, focusing on their oral C5aR inhibitor INF904.
AI Summary
On June 5, 2024, InflaRx N.V. hosted a virtual R&D event to highlight the potential of its drug candidate INF904. The company presented its corporate presentation on immuno-dermatology, providing updates and details on INF904, an oral C5aR inhibitor.
Why It Matters
This event provides investors and the scientific community with updated information on InflaRx's key drug candidate, INF904, potentially impacting its valuation and future development trajectory.
Risk Assessment
Risk Level: low — The filing is an informational update about an R&D event, not a material financial event.
Key Players & Entities
- InflaRx N.V. (company) — Registrant
- INF904 (drug_candidate) — Focus of R&D event
- June 5, 2024 (date) — Date of R&D event and press release
FAQ
What is INF904 and what is its mechanism of action?
INF904 is an oral C5aR inhibitor being developed by InflaRx, as highlighted in their R&D event and corporate presentation.
What was the purpose of the R&D event hosted by InflaRx on June 5, 2024?
The purpose was to highlight the promise of INF904 and provide details and developments on the drug candidate during a virtual R&D event and corporate presentation.
What type of drug is INF904?
INF904 is described as an oral C5aR inhibitor.
What is the company's focus area mentioned in the presentation?
The company's corporate presentation focused on immuno-dermatology.
What exhibits are attached to this 6-K filing?
The filing states that a press release titled 'InflaRx Hosts R&D Event Highlighting the Promise of INF904' is attached as Exhibit 99.1, and a corporate presentation is also attached.
Filing Stats: 285 words · 1 min read · ~1 pages · Grade level 9.6 · Accepted 2024-06-05 17:07:57
Filing Documents
- ef20030621_6k.htm (6-K) — 10KB
- ef20030621_ex99-1.htm (EX-99.1) — 22KB
- ef20030621_ex99-2.htm (EX-99.2) — 147KB
- ef20030621_ex99-2slide1.jpg (GRAPHIC) — 129KB
- ef20030621_ex99-2slide2.jpg (GRAPHIC) — 361KB
- ef20030621_ex99-2slide3.jpg (GRAPHIC) — 159KB
- ef20030621_ex99-2slide4.jpg (GRAPHIC) — 122KB
- ef20030621_ex99-2slide5.jpg (GRAPHIC) — 137KB
- ef20030621_ex99-2slide6.jpg (GRAPHIC) — 142KB
- ef20030621_ex99-2slide7.jpg (GRAPHIC) — 107KB
- ef20030621_ex99-2slide8.jpg (GRAPHIC) — 176KB
- ef20030621_ex99-2slide9.jpg (GRAPHIC) — 123KB
- ef20030621_ex99-2slide10.jpg (GRAPHIC) — 146KB
- ef20030621_ex99-2slide11.jpg (GRAPHIC) — 135KB
- ef20030621_ex99-2slide12.jpg (GRAPHIC) — 141KB
- ef20030621_ex99-2slide13.jpg (GRAPHIC) — 84KB
- ef20030621_ex99-2slide14.jpg (GRAPHIC) — 81KB
- ef20030621_ex99-2slide15.jpg (GRAPHIC) — 102KB
- ef20030621_ex99-2slide16.jpg (GRAPHIC) — 110KB
- ef20030621_ex99-2slide17.jpg (GRAPHIC) — 106KB
- ef20030621_ex99-2slide18.jpg (GRAPHIC) — 124KB
- ef20030621_ex99-2slide19.jpg (GRAPHIC) — 95KB
- ef20030621_ex99-2slide20.jpg (GRAPHIC) — 85KB
- ef20030621_ex99-2slide21.jpg (GRAPHIC) — 161KB
- ef20030621_ex99-2slide22.jpg (GRAPHIC) — 116KB
- ef20030621_ex99-2slide23.jpg (GRAPHIC) — 96KB
- ef20030621_ex99-2slide24.jpg (GRAPHIC) — 102KB
- ef20030621_ex99-2slide25.jpg (GRAPHIC) — 190KB
- ef20030621_ex99-2slide26.jpg (GRAPHIC) — 113KB
- ef20030621_ex99-2slide27.jpg (GRAPHIC) — 129KB
- ef20030621_ex99-2slide28.jpg (GRAPHIC) — 132KB
- ef20030621_ex99-2slide29.jpg (GRAPHIC) — 158KB
- ef20030621_ex99-2slide30.jpg (GRAPHIC) — 162KB
- ef20030621_ex99-2slide31.jpg (GRAPHIC) — 161KB
- ef20030621_ex99-2slide32.jpg (GRAPHIC) — 69KB
- ef20030621_ex99-2slide33.jpg (GRAPHIC) — 96KB
- ef20030621_ex99-2slide34.jpg (GRAPHIC) — 121KB
- ef20030621_ex99-2slide35.jpg (GRAPHIC) — 171KB
- ef20030621_ex99-2slide36.jpg (GRAPHIC) — 115KB
- ef20030621_ex99-2slide37.jpg (GRAPHIC) — 103KB
- ef20030621_ex99-2slide38.jpg (GRAPHIC) — 155KB
- ef20030621_ex99-2slide39.jpg (GRAPHIC) — 133KB
- ef20030621_ex99-2slide40.jpg (GRAPHIC) — 166KB
- ef20030621_ex99-2slide41.jpg (GRAPHIC) — 109KB
- ef20030621_ex99-2slide42.jpg (GRAPHIC) — 94KB
- ef20030621_ex99-2slide43.jpg (GRAPHIC) — 148KB
- ef20030621_ex99-2slide44.jpg (GRAPHIC) — 174KB
- ef20030621_ex99-2slide45.jpg (GRAPHIC) — 116KB
- ef20030621_ex99-2slide46.jpg (GRAPHIC) — 140KB
- ef20030621_ex99-2slide47.jpg (GRAPHIC) — 102KB
- ef20030621_ex99-2slide48.jpg (GRAPHIC) — 165KB
- ef20030621_ex99-2slide49.jpg (GRAPHIC) — 121KB
- ef20030621_ex99-2slide50.jpg (GRAPHIC) — 104KB
- ef20030621_ex99-2slide51.jpg (GRAPHIC) — 140KB
- ef20030621_ex99-2slide52.jpg (GRAPHIC) — 107KB
- ef20030621_ex99-2slide53.jpg (GRAPHIC) — 139KB
- ef20030621_ex99-2slide54.jpg (GRAPHIC) — 225KB
- ef20030621_ex99-2slide55.jpg (GRAPHIC) — 114KB
- ef20030621_ex99-2slide56.jpg (GRAPHIC) — 133KB
- ef20030621_ex99-2slide57.jpg (GRAPHIC) — 124KB
- ef20030621_ex99-2slide58.jpg (GRAPHIC) — 125KB
- ef20030621_ex99-2slide59.jpg (GRAPHIC) — 158KB
- ef20030621_ex99-2slide60.jpg (GRAPHIC) — 140KB
- ef20030621_ex99-2slide61.jpg (GRAPHIC) — 144KB
- ef20030621_ex99-2slide62.jpg (GRAPHIC) — 127KB
- ef20030621_ex99-2slide63.jpg (GRAPHIC) — 121KB
- ef20030621_ex99-2slide64.jpg (GRAPHIC) — 86KB
- ef20030621_ex99-2slide65.jpg (GRAPHIC) — 105KB
- ef20030621_ex99-2slide66.jpg (GRAPHIC) — 141KB
- ef20030621_ex99-2slide67.jpg (GRAPHIC) — 112KB
- ef20030621_ex99-2slide68.jpg (GRAPHIC) — 119KB
- ef20030621_ex99-2slide69.jpg (GRAPHIC) — 37KB
- ef20030621_ex99-2slide70.jpg (GRAPHIC) — 119KB
- ef20030621_ex99-2slide71.jpg (GRAPHIC) — 83KB
- ef20030621_ex99-2slide72.jpg (GRAPHIC) — 114KB
- ef20030621_ex99-2slide73.jpg (GRAPHIC) — 132KB
- ef20030621_ex99-2slide74.jpg (GRAPHIC) — 127KB
- ef20030621_ex99-2slide75.jpg (GRAPHIC) — 117KB
- ef20030621_ex99-2slide76.jpg (GRAPHIC) — 118KB
- ef20030621_ex99-2slide77.jpg (GRAPHIC) — 112KB
- ef20030621_ex99-2slide78.jpg (GRAPHIC) — 116KB
- ef20030621_ex99-2slide79.jpg (GRAPHIC) — 139KB
- ef20030621_ex99-2slide80.jpg (GRAPHIC) — 115KB
- ef20030621_ex99-2slide81.jpg (GRAPHIC) — 116KB
- ef20030621_ex99-2slide82.jpg (GRAPHIC) — 114KB
- ef20030621_ex99-2slide83.jpg (GRAPHIC) — 95KB
- ef20030621_ex99-2slide84.jpg (GRAPHIC) — 108KB
- ef20030621_ex99-2slide85.jpg (GRAPHIC) — 109KB
- ef20030621_ex99-2slide86.jpg (GRAPHIC) — 43KB
- ef20030621_ex99-2slide87.jpg (GRAPHIC) — 112KB
- image00001.jpg (GRAPHIC) — 3KB
- 0001140361-24-029023.txt ( ) — 15305KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INFLARX N.V. Date: June 5, 2024 By: /s/ Niels Riedemann Name: Niels Riedemann Title: Chief Executive Officer